Examination of utility of minodronic acid hydrate to osteoporosis by ovarian insufficiency after gynecologic disease treatment

Examination of utility of minodronic acid hydrate to osteoporosis by ovarian insufficiency after gynecologic disease treatment - Examination of utility of minodronic acid hydrate to osteoporosis after gynecologic disease treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008353

Enrollment

Registered

2012-07-09

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis after gynecologic disease treatment

Interventions

Administering minodronic acid hydrate Bonoteo Tablets 50mg once a month for two years

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Cases that diagnosed as bone loss and osteoporosis ,and that have a more than 15% probability of bone fracture in the next 10 years by FRAX ,is a diagnostic tool used to evaluate bone fracture risk, by ovarian insufficiency after gynecologic disease treatment

Exclusion criteria

Exclusion criteria: 1)Cases with a history of serious drug sensitivity or allergy 2)Cases with diseases that are likely to delay esophageal transit such as esophagus stenosis or achalasia 3)Cases that cannot keep upright or sitting positioning for 30 minutes or more when taking it 4)Cases that be judged inadequate for for this study

Design outcomes

Primary

Measure	Time frame
The changes of bone mineral density and biochemical markers of turnover after two years from administering beginning	—

Countries

Japan

Contacts

Public ContactSugiyama Michiyo

Gifu University Obstetrics and Gynecology

michiyo@gifu-u.ac.jp058-230-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026